IOSP logo

Innospec (IOSP) Cash And Cash Equivalents

Annual Cash & Cash Equivalents

$203.70 M
+$56.60 M+38.48%

December 31, 2023


Summary


Performance

IOSP Cash And Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherIOSPbalance sheetmetrics:

Quarterly Cash And Cash Equivalents

$303.80 M
+$63.60 M+26.48%

September 30, 2024


Summary


Performance

IOSP Quarterly Cash And Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherIOSPbalance sheetmetrics:

Cash And Cash Equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

IOSP Cash And Cash Equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+38.5%+26.5%
3 y3 years+93.5%+187.7%
5 y5 years+65.5%+188.5%

IOSP Cash And Cash Equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+43.6%at high+325.5%
5 y5-yearat high+169.1%at high+422.0%
alltimeall timeat high+1365.5%at high+2085.6%

Innospec Cash And Cash Equivalents History

DateAnnualQuarterly
Sep 2024
-
$303.80 M(+26.5%)
Jun 2024
-
$240.20 M(-11.1%)
Mar 2024
-
$270.10 M(+32.6%)
Dec 2023
$203.70 M(+38.5%)
$203.70 M(-1.7%)
Sep 2023
-
$207.20 M(+24.9%)
Jun 2023
-
$165.90 M(+12.5%)
Mar 2023
-
$147.50 M(+0.3%)
Dec 2022
$147.10 M(+3.7%)
$147.10 M(+46.4%)
Sep 2022
-
$100.50 M(+40.8%)
Jun 2022
-
$71.40 M(-32.4%)
Mar 2022
-
$105.60 M(-25.5%)
Dec 2021
$141.80 M(+34.7%)
$141.80 M(+59.0%)
Sep 2021
-
$89.20 M(-5.5%)
Jun 2021
-
$94.40 M(-19.3%)
Mar 2021
-
$117.00 M(+11.1%)
Dec 2020
$105.30 M(+39.1%)
$105.30 M(+58.1%)
Sep 2020
-
$66.60 M(+14.4%)
Jun 2020
-
$58.20 M(-14.5%)
Mar 2020
-
$68.10 M(-10.0%)
Dec 2019
$75.70 M(-38.5%)
$75.70 M(-31.4%)
Sep 2019
-
$110.30 M(+4.0%)
Jun 2019
-
$106.10 M(-14.1%)
Mar 2019
-
$123.50 M(+0.3%)
Dec 2018
$123.10 M(+36.5%)
$123.10 M(+34.7%)
Sep 2018
-
$91.40 M(+38.5%)
Jun 2018
-
$66.00 M(-15.5%)
Mar 2018
-
$78.10 M(-13.4%)
Dec 2017
$90.20 M(-11.5%)
$90.20 M(+37.7%)
Sep 2017
-
$65.50 M(+34.2%)
Jun 2017
-
$48.80 M(+7.5%)
Mar 2017
-
$45.40 M(-55.4%)
Dec 2016
$101.90 M(-25.6%)
$101.90 M(-39.0%)
Sep 2016
-
$167.10 M(+9.1%)
Jun 2016
-
$153.20 M(+35.1%)
Mar 2016
-
$113.40 M(-17.2%)
Dec 2015
$136.90 M(+229.1%)
$136.90 M(+7.2%)
Sep 2015
-
$127.70 M(+98.6%)
Jun 2015
-
$64.30 M(+38.3%)
Mar 2015
-
$46.50 M(+11.8%)
Dec 2014
$41.60 M(-48.1%)
$41.60 M(-54.0%)
Sep 2014
-
$90.40 M(-1.1%)
Jun 2014
-
$91.40 M(+1.4%)
Mar 2014
-
$90.10 M(+12.3%)
Dec 2013
$80.20 M(+258.0%)
$80.20 M(+48.8%)
Sep 2013
-
$53.90 M(-1.5%)
Jun 2013
-
$54.70 M(+26.6%)
Mar 2013
-
$43.20 M(+92.9%)
Dec 2012
$22.40 M(-70.6%)
$22.40 M(-82.7%)
Sep 2012
-
$129.60 M(+22.5%)
Jun 2012
-
$105.80 M(+16.0%)
Mar 2012
-
$91.20 M(+19.7%)
Dec 2011
$76.20 M
$76.20 M(-42.3%)
Sep 2011
-
$132.10 M(+33.4%)
DateAnnualQuarterly
Jun 2011
-
$99.00 M(+10.1%)
Mar 2011
-
$89.90 M(-16.1%)
Dec 2010
$107.10 M(+56.1%)
$107.10 M(+8.4%)
Sep 2010
-
$98.80 M(+34.1%)
Jun 2010
-
$73.70 M(+14.8%)
Mar 2010
-
$64.20 M(-6.4%)
Dec 2009
$68.60 M(+393.5%)
$68.60 M(+36.7%)
Sep 2009
-
$50.20 M(+12.8%)
Jun 2009
-
$44.50 M(+25.4%)
Mar 2009
-
$35.50 M(+155.4%)
Dec 2008
$13.90 M(-42.8%)
$13.90 M(-8.6%)
Sep 2008
-
$15.20 M(-7.3%)
Jun 2008
-
$16.40 M(+16.3%)
Mar 2008
-
$14.10 M(-42.0%)
Dec 2007
$24.30 M(-76.2%)
$24.30 M(-14.1%)
Sep 2007
-
$28.30 M(-18.7%)
Jun 2007
-
$34.80 M(+0.3%)
Mar 2007
-
$34.70 M(-65.9%)
Dec 2006
$101.90 M(+47.9%)
$101.90 M(+10.9%)
Sep 2006
-
$91.90 M(+39.7%)
Jun 2006
-
$65.80 M(+10.2%)
Mar 2006
-
$59.70 M(-13.4%)
Dec 2005
$68.90 M(+106.9%)
$68.90 M(+6.7%)
Sep 2005
-
$64.60 M(+130.7%)
Jun 2005
-
$28.00 M(-38.6%)
Mar 2005
-
$45.60 M(+36.9%)
Dec 2004
$33.30 M(-27.8%)
$33.30 M(-4.3%)
Sep 2004
-
$34.80 M(-55.6%)
Jun 2004
-
$78.30 M(+15.3%)
Mar 2004
-
$67.90 M(+47.3%)
Dec 2003
$46.10 M(+72.7%)
$46.10 M(+4.5%)
Sep 2003
-
$44.10 M(+53.7%)
Jun 2003
-
$28.70 M(-8.3%)
Mar 2003
-
$31.30 M(+17.2%)
Dec 2002
$26.70 M(-37.9%)
$26.70 M(-13.9%)
Sep 2002
-
$31.00 M(+14.8%)
Jun 2002
-
$27.00 M(+6.3%)
Mar 2002
-
$25.40 M(-40.9%)
Dec 2001
$43.00 M(+14.1%)
$43.00 M(-2.3%)
Sep 2001
-
$44.00 M(+41.5%)
Jun 2001
-
$31.10 M(-52.9%)
Mar 2001
-
$66.00 M(+75.1%)
Dec 2000
$37.70 M(+1.3%)
$37.70 M(-8.9%)
Sep 2000
-
$41.40 M(-27.4%)
Jun 2000
-
$57.00 M(+32.6%)
Mar 2000
-
$43.00 M(+15.6%)
Dec 1999
$37.20 M(+40.4%)
$37.20 M(+44.2%)
Sep 1999
-
$25.80 M(+61.3%)
Jun 1999
-
$16.00 M(-48.9%)
Mar 1999
-
$31.30 M(+18.1%)
Dec 1998
$26.50 M
$26.50 M(-46.6%)
Sep 1998
-
$49.60 M(+18.1%)
Jun 1998
-
$42.00 M(+26.1%)
Mar 1998
-
$33.30 M

FAQ

  • What is Innospec annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Innospec?
  • What is Innospec annual cash & cash equivalents year-on-year change?
  • What is Innospec quarterly cash and cash equivalents?
  • What is the all time high quarterly cash and cash equivalents for Innospec?
  • What is Innospec quarterly cash and cash equivalents year-on-year change?

What is Innospec annual cash & cash equivalents?

The current annual cash & cash equivalents of IOSP is $203.70 M

What is the all time high annual cash & cash equivalents for Innospec?

Innospec all-time high annual cash & cash equivalents is $203.70 M

What is Innospec annual cash & cash equivalents year-on-year change?

Over the past year, IOSP annual cash & cash equivalents has changed by +$56.60 M (+38.48%)

What is Innospec quarterly cash and cash equivalents?

The current quarterly cash and cash equivalents of IOSP is $303.80 M

What is the all time high quarterly cash and cash equivalents for Innospec?

Innospec all-time high quarterly cash and cash equivalents is $303.80 M

What is Innospec quarterly cash and cash equivalents year-on-year change?

Over the past year, IOSP quarterly cash and cash equivalents has changed by +$63.60 M (+26.48%)